Phoenix Canada Oil Company Limited (V:PCO*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 204 - 407 Downey Road
SASKATOON SK S7N 4L8
Tel: N/A
Website: https://www.zyus.com
IR: See website
<
Key People
Charlotte Moore Hepburn
Chairman of the Board
Brent Zettl
President, Chief Executive Officer
Michael D. Kindy
Chief Financial Officer
Business Overview
ZYUS Life Sciences Corporation is a Canada-based life sciences company. The Company is focused on the global development and commercialization of cannabinoid-based pharmaceutical drug product candidates and exempt market therapeutics. Through clinical research, it is committed to furthering the understanding of cannabinoids with the clinical development of its pharmaceutical drug product candidates and intellectual property activities to protect its novel formulations. Additionally, the Company delivers cGMP / EU GMP-compliant cannabinoid products to patients through the exempt global medical market. The Company is also focused on commercialization of its exempt market therapeutics, such as cannabinoid oils, soft gel capsules and topical creams, in Canada and those international markets where medical cannabis is legal.
Financial Overview
For the nine months ended 30 September 2023, ZYUS Life Sciences Corp revenues increased from C$0K to C$254K. Net loss increased from C$350K to C$18.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Listing expense increase from C$0K to C$2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -C$0.07 to -C$0.29.
Employees: 2 as of Dec 31, 2005
Reporting Currency: Canadian Dollars
Enterprise value: $71.33M as of Dec 31, 2023
Annual revenue (TTM): $0.25M as of Dec 31, 2023
EBITDA (TTM): -$9.83M as of Dec 31, 2023
Net annual income (TTM): -$18.12M as of Dec 31, 2023
Free cash flow (TTM): -$15.25M as of Dec 31, 2023
Net Debt Last Fiscal Year: $1.75M as of Dec 31, 2023
Shares outstanding: 70,847,396 as of Jan 2, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.